Gino Santini has served as a member of our board of directors since February 2012. Mr. Santini is the Chairman of the board of directors of AMAG Pharmaceuticals (NASDAQ: AMAG), and a member of the board of directors of Horizon Pharma plc (NASDAQ: HZNP), Intercept Pharmaceuticals (NASDAQ: ICPT), Collegium Pharmaceuticals (NASDAQ: COLL), Intarcia Therapeutics, and Artax Biopharma. He previously served on the boards of SORIN SpA (SRN.MI) and Vitae Pharmaceuticals (NASDAQ: VTAE) until their acquisitions. Mr. Santini has been an advisor of European and US venture capital, pharmaceutical and biotechnology companies since 2011, when he retired after a 27-year career at Eli Lilly. Mr. Santini’s last role at Eli Lilly was Senior Vice President of corporate strategy and business development. Mr. Santini holds a degree in Mechanical Engineering from the University of Bologna and an M.B.A. from the Simon School of Business, University of Rochester. We believe that Mr. Santini’s long career at Eli Lilly and extensive domestic and international commercial, corporate strategy, business development and transaction experience are valuable skill sets for the board.
Chairman of the Board